Amgen rating outlook negative, was stable -Moody's

(Reuters) - "Amgen's financial policies are aggressive at a time when
its operating risk profile has increased and its cash flows
face new uncertainties," Moody's analyst Michael Levesque said
in a statement.




Safety issues have clouded the outlook for sales of Amgen's
biggest product, Aranesp, and its older drug Epogen, both used
to treat anemia.


Read more at Reuters.com Bonds News